JP2018516586A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516586A5
JP2018516586A5 JP2017564369A JP2017564369A JP2018516586A5 JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5 JP 2017564369 A JP2017564369 A JP 2017564369A JP 2017564369 A JP2017564369 A JP 2017564369A JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5
Authority
JP
Japan
Prior art keywords
interleukin
growth factor
activity
nanograms
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564369A
Other languages
English (en)
Japanese (ja)
Other versions
JP6799895B2 (ja
JP2018516586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063077 external-priority patent/WO2016198480A1/en
Publication of JP2018516586A publication Critical patent/JP2018516586A/ja
Publication of JP2018516586A5 publication Critical patent/JP2018516586A5/ja
Application granted granted Critical
Publication of JP6799895B2 publication Critical patent/JP6799895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564369A 2015-06-09 2016-06-08 ＴＣＲγδ＋Ｔ細胞の生産方法 Active JP6799895B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PT20151000047568 2015-06-09
PT2015047568 2015-06-09
PT20161000032002 2016-05-12
PT2016032002 2016-05-12
PCT/EP2016/063077 WO2016198480A1 (en) 2015-06-09 2016-06-08 Methods for the production of tcr gamma delta+ t cells

Publications (3)

Publication Number Publication Date
JP2018516586A JP2018516586A (ja) 2018-06-28
JP2018516586A5 true JP2018516586A5 (https=) 2019-07-11
JP6799895B2 JP6799895B2 (ja) 2020-12-16

Family

ID=56132913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564369A Active JP6799895B2 (ja) 2015-06-09 2016-06-08 ＴＣＲγδ＋Ｔ細胞の生産方法

Country Status (9)

Country Link
US (2) US11166983B2 (https=)
EP (2) EP3307875B1 (https=)
JP (1) JP6799895B2 (https=)
CN (2) CN108350428B (https=)
AU (3) AU2016274633B2 (https=)
CA (1) CA2988050A1 (https=)
EA (1) EA201890013A1 (https=)
WO (1) WO2016198480A1 (https=)
ZA (1) ZA201800121B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
KR102663157B1 (ko) 2015-06-09 2024-05-13 감마델타 테라퓨틱스 엘티디 Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법
EP4148124A1 (en) * 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
AU2019354391A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
CN113272016A (zh) 2018-10-01 2021-08-17 阿迪塞特生物股份有限公司 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
US20220088074A1 (en) * 2019-02-21 2022-03-24 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
MX2021015448A (es) * 2019-06-14 2022-06-08 G Tech Bio Llc Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
EP4045635A4 (en) * 2019-10-17 2023-10-25 The University of Hong Kong METHODS FOR PREPARING EXOSOMES DERIVED FROM T-V LYMPHOCYTES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH EPSTEIN-BARR VIRUS
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
CN113913384A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 一种制备靶点特异性nk细胞的方法及其应用
EP4198120A4 (en) * 2020-08-14 2024-05-08 Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND THEIR USE
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
CA3202233A1 (en) * 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
TW202246338A (zh) * 2021-02-17 2022-12-01 英商適應生物治療有限公司 抗ＴＣＲδ可變1抗體
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
KR20240040799A (ko) 2021-08-03 2024-03-28 감마델타 테라퓨틱스 엘티디 감마 델타 t 세포 및 이의 조성물의 조작
MX2024010047A (es) 2022-02-16 2024-08-26 Priothera Sas Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.
WO2023194915A1 (en) 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Novel gene armoring
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
US11750950B1 (en) * 2022-05-26 2023-09-05 Omnivision Technologies, Inc. Voltage domain global shutter readout circuit timing
CN115678846B (zh) * 2022-09-01 2023-06-16 广东龄值生物科技有限公司 一种肿瘤特异性γδT细胞及其制备方法
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
EP4687923A1 (en) 2023-04-07 2026-02-11 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2026013616A1 (en) 2024-07-10 2026-01-15 Takeda Pharmaceutical Company Limited Compositions and methods for treating cancer
WO2026033421A1 (en) 2024-08-05 2026-02-12 Takeda Pharmaceutical Company Limited IDENTIFICATION OF SUITABLE DONORS OF γδ T CELLS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537812B1 (en) * 1998-11-04 2003-03-25 Hemosol Inc. Methods for the production of TcRγδ+ T cells
ATE449162T1 (de) 2000-04-03 2009-12-15 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
US20030157060A1 (en) 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
EP1778836B1 (en) * 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
CN101313061B (zh) * 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
WO2008111430A1 (ja) * 2007-03-09 2008-09-18 Takara Bio Inc. γδＴ細胞集団の製造方法
BR112013009454B1 (pt) 2010-10-21 2018-10-23 Syngenta Limited método para redução da viscosidade de um concentrado agroquímico aquoso, concentrado agroquímico aquoso, utilização de um sulfonato de arila e isopirazam para redução da viscosidade de um concentrado agroquímico aquoso e método para controlar ou prevenir a infestação de plantas por micro-organismos fitopatógenos
CN103635573B (zh) * 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
EP3484862B1 (en) 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
CN106399245A (zh) * 2016-11-30 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种γδT细胞的培养方法

Similar Documents

Publication Publication Date Title
JP2018516586A5 (https=)
Kaur et al. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs
Kratchmarov et al. TCF1 expression marks self-renewing human CD8+ T cells
Li et al. Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma
Meng et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application
Wang et al. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy
Icheva et al. Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation
Muliaditan et al. Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer
Orange et al. Coley’s lessons remembered: augmenting mistletoe therapy
Marçais et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells
Jin et al. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
Vacchelli et al. Trial Watch—Immunostimulation with cytokines in cancer therapy
WO2012156958A4 (en) Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
Draghiciu et al. Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
Sköld et al. Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
Weir et al. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
AU2020353154A1 (en) Compositions comprising regulatory T cells and methods of making and using the same
US20230066340A1 (en) Populations of enriched regulatory t cells and methods for producing same
Tuthill et al. Thymosin α1 continues to show promise as an enhancer for vaccine response
Clark et al. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases
CN117377755A (zh) 包含调节性t细胞的组合物及其使用方法
Liu et al. IL-2/GM-CSF enhances CXCR3 expression in car-T cells via the PI3K/akt and ERK1/2 pathways
Bialek-Waldmann et al. Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre-or post-stem cell transplantation
Li et al. Dendritic cells therapy with cytokine-induced killer cells and activated cytotoxic T cells attenuated Th2 bias immune response
CN109136182A (zh) 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用